Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18584349 | 0.92 | TSHR (0.37) | TSHRALDH1A1LMNAOPRM1SMN1; SMN2 | |
| SCHEMBL19432796 | 0.89 | TSHR (0.42) | TSHRALDH1A1LMNATHRBFDPS | |
| SCHEMBL20609962 | 0.89 | TSHR (0.42) | TSHRALDH1A1LMNATHRBFDPS | |
| SCHEMBL1263906 | 0.89 | TSHR (0.42) | TSHRALDH1A1LMNATHRBFDPS | |
| SCHEMBL7892883 | 0.86 | — | — | |
| SCHEMBL583105 | 0.81 | — | — | |
| SCHEMBL6060603 | 0.81 | FFAR1 (0.31) | TDP1 | |
| SCHEMBL9630699 | 0.78 | TSHR (0.31) | TSHRALDH1A1LMNATDP1SMN1; SMN2 | |
| SCHEMBL18125160 | 0.78 | ALDH1A1 (0.36) | TSHRALDH1A1LMNATDP1SMN1; SMN2 | |
| SCHEMBL21925358 | 0.78 | TSHR (0.30) | TSHRALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-05 | — | — | US | claimed |
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | SUPER CRITICAL IP, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4473046-B1 | METHODS FOR PURIFYING A RECLAIMED POLYMER | DOW GLOBAL TECHNOLOGIES LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260041617-A1 | COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2026-02-12 | — | — | US | disclosed |
| US-12503662-B1 | Cyclooctane containing seal swelling compositions and methods for use of same | CleanJoule, Inc. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250177263-A1 | LIPSTICK COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2025-06-05 | — | — | US | disclosed |
| US-20250170037-A1 | EYE MAKEUP COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250152646-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS | NOEL ARMAND J (US) | 2025-05-15 | — | — | US | disclosed |
| EP-0274064-A2 | 2,5,6,7-Tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1988-07-13 | — | — | EP | disclosed |
| US-4713384-A | HYPOTENSIVE AND ANTIMIGRAINE AGENTS | ELI LILLY AND COMPANY (US) | 1987-12-15 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
| EP-0218433-A1 | Selective method for blocking 5HT2 receptors | ELI LILLY AND COMPANY (US) | 1987-04-15 | — | — | EP | disclosed |
| US-4636243-A | HERBICIDES ISOXAZOLES | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4515625-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0049071-B1 | N-ARYLBENZAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1984-12-19 | — | — | EP | disclosed |
| US-4416683-A | HERBICIDES | ELI LILLY AND COMPANY (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0049071-A1 | N-arylbenzamide derivatives | ELI LILLY AND COMPANY (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | CNR2, CNR1, SCD | TSHR 2794/4885ALDH1A1 4135/4885LMNA 408/4885 |
| US-20260041617-A1 | COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES | CUTA, AP2M1, LBR | TSHR 612/4885ALDH1A1 134/4885LMNA 1250/4885 |
| US-12503662-B1 | Cyclooctane containing seal swelling compositions and methods for use of same | AQP1, GJA1, DSC1 | TSHR 4878/4885ALDH1A1 4567/4885LMNA 2457/4885 |
| US-20260062631-A1 | CYCLOOCTANE CONTAINING FUEL COMPOSITIONS | CPT1A, CPT2, CNR2 | TSHR 3620/4885ALDH1A1 3269/4885LMNA 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.